Gallic acid is a known antioxidant and has anti-inflammatory activity in addition to other biological activities, but GA efficiency is restricted due to low permeability and low oral bioavailability. This study was designed to investigate the solubility, permeability, oral bioavailability, enzymatic stability with cytochrome CYP2D6, antioxidant and anti-inflammatory activity of novel gallic acid sulfonamide derivatives; TMBS, and THBS. In addition, a novel in silico permeability model was designed to predict the permeability and bioavailability of eighty derivatives of GA. In sillico prediction of intestinal permeability of GA derivative indicated an increase in permeability with increased lipophilicity and decreased aqueous solubility, replacing the carboxylic group with sulfonamide group has increased intestinal permeability. A significant (P <0.01) increase was observed in the permeability of TMBS and THBS over GA, in both gastric fluids and HIEC cells. TMBS was O-demethylated by CYP2D6. TMBS had greater ROS scavenging activity than GA in HIEC-6 cells. There was a significant (P< 0.05) increase in anti-inflammatory activity of THBS, and TMBS compared to ibuprofen. TMBS, and THBS had better oral bioavailability than GA. This data suggests that the in silico permeability model can be used in the future to study new candidate of gallic acid, and further in vivo and clinical investigations are required to introduce TMBS and THBS as a new antioxidant and anti-inflammatory drugs.